MERZ-AESTHETICS
Merz Aesthetics is presenting at the 2024 International Master Course on Aging Science (IMCAS) World Congress a total of 5 abstracts highlighting the field of regenerative aesthetics and how its product portfolio is contributing. This year’s IMCAS is the 25th edition of the largest scientific aesthetics congress worldwide beginning Thursday, February 1st to Saturday, February 3.
“Merz Aesthetics is looking forward to sharing these new findings, as they provide strong scientific evidence to support the evolving field of regenerative aesthetics,” said Terri Phillips, M.D., Chief Medical Affairs Officer, Merz Aesthetics. “We take pride in the innovation of our product portfolio and how it’s helping to shape the future of the aesthetics industry.”
“Our focus in this year’s Merz Aesthetics sponsored symposium at the IMCAS Congress is the future of regenerative biostimulation with Radiesse”, said Gonzalo Mibelli, President EMEA, Merz Aesthetics. “Together with a panel of renowned industry experts we discuss the topic of skin regeneration, share insights into techniques and personalized treatment approaches aligned with our Merz Aesthetics commitment on scientific exchange and innovation.”
Merz Aesthetics organized a program led by notable medical aesthetic experts, participating in various IMCAS sessions and presenting new data throughout the event.
- Merz Aesthetics sponsored symposium “Mastering regenerative biostimulation” – Dr. Gabriela Casabona, Dr. Tatjana Pavicic, Dr. Jani van Loghem, Dr. Bianca Viscomi, Friday, February 2, 2024, 4:00 p.m. – 6:00 p.m. CEST
- Merz Aesthetics support of IMCAS Cadaver Workshop – Anatomist Dr. Nicholas Moellhoff and Aesthetic Specialist Dr. Jonathan Kadouch, Thursday, February 1, 2024, 2:30 p.m. – 3:30 p.m. CEST
- IMCAS Product Analysis Session “Biostimulators” – Dr. Alec McCarthy, Director Regenerative Aesthetics, Merz Aesthetics, Friday, February 2, 2024, 8:30 a.m. ‒ 10:00 a.m. CEST
- IMCAS Product Analysis Session “Toxins” – PH.D. Andy Curry, associate medical director, Merz Aesthetics, Saturday, February 3, 2024, 8:30 a.m. ‒ 10:00 a.m. CEST
- IMCAS Economic Tribune Roundtable – Bob Rhatigan, CEO Merz Aesthetics, Friday, February 2, 2024, 2:00 p.m. – 3:30 p.m. CEST
Booth Talks
- Treatment Options for Hand Rejuvenation - Dr. Elena Bagnenko, Thursday, February 1, 2024, 1:00p.m. – 1.30 p.m.
- Innovative Technique for Tear Trough Correction - Dr. Yahia Hashish, Thursday, February 1, 2024, 3:30p.m. – 4.00 p.m.
- What are THE Really Important Aspects when using CaHA as a Regenerative Biostimulator? - Dr. Gabriela Casabona, Friday, February 2, 10:00 a.m. – 10.30 a.m.
- Advancing Skin Radiance, Dr. Juan Martín Zárate González, Friday, February 2, 1:00 p.m. – 1.30 p.m.
- Combination of Treatments for Improving Skin Quality - Dr. Ana Diez Gandia, Saturday, February 3, 2024, 10:00 a.m. – 10.30 a.m.
E-Poster Presentations
Virtual posters will be available for viewing on-site throughout the congress and displayed on the virtual e-poster platform with detailed abstracts.
- A review of Radiesse as a regenerative aesthetic treatment. Presenting author: Dr. Shino Bay Aguilera. Co-Authors: Dr. Alec McCarthy, Dr. Saami Khalifian, Dr.Z. Paul Lorenc, Dr. Katherine Goldie, Dr. W. Gregory Chernoff
- The evolving field of regenerative aesthetics. Presenting author: Dr. Katherine Goldie
- Physical properties of diluted Radiesse. Presenting author: Dr. Vasanop Vachiramon. Co-authors: Dr. Chayanee Likitwattananurak, Dr. Nawara Sakpuwadol, Dr. Tanat Yongpisarn
- Attraction of fibroblasts by Micro-Focused Ultrasound (MFU-V). Presenting author: Dr. Kay Marquardt. Co-authors: Dr. F. Wegener, Dr. Nils Warfving, Dr. Christian Hartmann, Dr. Dr. Thomas Hengl
- Retrospective case series following patients treated with a combination of CPM-HA and CaHA fillers. Presenting author: Dr. Bianca Viscomi Co-authors: Dr. Yana Yutskovskaya, Dr. Heidi Waldorf, Dr. Ting Song Lim
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2024 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201288217/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 202622.1.2026 07:00:00 CET | Press release
Five presentations will showcase nizubaglustat’s therapeutic potential in Lysosomal Storage Disorders. Nizubaglustat is currently being tested in two global Phase 3 studies for Niemann-Pick type C disease and GM1/GM2 gangliosidoses which are currently recruiting. Azafaros will host a satellite symposium on nizubaglustat on Day 2 of the symposium discussing the Phase 3 studies. WORLDSymposium™ 2026 takes place from February 2 to 6 in San Diego, California. Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that its lead asset, nizubaglustat, will feature in five scientific presentations accepted at the WORLDSymposium™ 2026, the leading global conference on lysosomal diseases, taking place in San Diego, California, USA between February 2-6. The company’s conference activities include: Oral Presentations (including Poster numbers 134 and 29-C) Long-term data from a Phase II study wit
I Squared Announces Launch of Radiant Energy Solutions22.1.2026 07:00:00 CET | Press release
I Squared Capital (“I Squared”), a leading global infrastructure investment manager, announced today the launch of Radiant Energy Solutions (“Radiant”), an investment from I Squared’s Middle East infrastructure strategy, which is focused on targeting transformational, mid-market investments in the region. Reflecting I Squared’s platform-building approach of starting with a core initial investment and scaling over time to build market-leading businesses, Radiant marks the firm’s entry into the Middle East distributed renewables market, providing decarbonization solutions to commercial and industrial customers. The investment for Radiant is the acquisition of FAS Renewables and its 100% owned subsidiary Zahra Energy, a Saudi Arabia–based distributed solar company with a secured and advanced portfolio of over 100MWp of distributed solar projects with established customers and long-term contracted solar power purchase agreements. These include Cenomi Centers, an owner, operator, and develo
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio22.1.2026 07:00:00 CET | Press release
At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas1-7 Multiple studies will reinforce the safety and efficacy of Galderma’s hyaluronic acid (HA) treatments range, including post-marketing data on Restylane® Shaype™ in shaping the chin, Restylane Lyft™ in improving jawline definition, Restylane Skinboosters™ in smoothing fine lines and wrinkles in the décolletage and Restylane Volyme™ in correcting hollowing of the temples8-11 New data on the innovative neuromodulator Relfydess™ (RelabotulinumtoxinA) will reinforce its rapid onset as early as Day 1 and sustained efficacy through six months for frown lines and crow’s feet12 As a leader in injectable aesthetic innovation, Galderma will showcase its superior science and edu
WEF26: Saudi Arabia Leads New Global Push to Protect Coral Reefs, Unlock AI Potential22.1.2026 05:52:00 CET | Press release
The Saudi delegation to the World Economic Forum (WEF) Annual Meeting 2026 today observed a series of announcements aimed at addressing urgent global challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121465066/en/ Her Royal Highness Ambassador Reema Bandar Al-Saud, Ambassador of the Kingdom of Saudi Arabia to the United States of America, announced at the World Economic Forum Annual Meeting that Saudi Arabia will host the first Global Coral Reef Summit in 2026 (Photo: AETOSWire) Her Royal Highness Ambassador Reema Bandar Al-Saud, Ambassador of the Kingdom of Saudi Arabia to the United States of America, announced that Saudi Arabia will host the first Global Coral Reef Summit in 2026, bringing together global leaders, scientists, and investors to drive solutions for the protection and recovery of coral reef ecosystems. The summit will address key challenges and policy and regulatory gaps, develop science-based sol
BitGo Holdings Announces Pricing of Initial Public Offering22.1.2026 03:38:00 CET | Press release
BitGo Holdings, Inc. (“BitGo”), the digital asset infrastructure company, announced today the pricing of its initial public offering of an aggregate of 11,821,595 shares of Class A common stock at a price to the public of $18.00 per share. The offering consists of 11,026,365 shares of Class A common stock being offered by BitGo and 795,230 shares of Class A common stock being offered by certain existing stockholders of BitGo. BitGo will not receive any proceeds from the sale of the shares by the selling stockholders in connection with the offering. In connection with the offering, BitGo has granted the underwriters a 30-day option to purchase up to an additional 1,770,000 shares of its Class A common stock at the public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the New York Stock Exchange on January 22, 2026 under the ticker symbol "BTGO" and the offering is expected to close on January 23, 2026, subject to customary closin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom